HITHOC – possibility of combined treatment of malignant pleural mesothelioma


Doc. MUDr. David Vrána, Ph.D.1; MUDr. Nikol Rušarová2; MUDr. Marek Szkorupa, Ph.D.3

1 Komplexní onkologické centrum, Nemocnice Nový Jičín

2 Onkologická klinika LF UP a FN Olomouc

3 I. chirurgická klinika LF UP a FN Olomouc



Malignant pleural mesothelioma represents a disease with poor prognosis. There is currently no accepted general standard of care however as available published data indicate the multimodality approach combining chemotherapy (neoadjuvant or adjuvant, based on cisplatin/carboplatin and pemetrexed), surgery and eventually perioperative pleural chemotherapy lavage seem to bring the most benefit. This approach is suitable for only limited group of patients in a good performance status, without any distant metastatic disease and without clinically significant comorbidities. Further research is therefore needed to define the optimal treatment algorithm for malignant pleural mesothelioma.


Key words

malignant pleural mesothelioma, HITHOC, multimodality approach



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...